Skip to main content

Advertisement

Table 3 Stages and Prior Systemic Therapies of DAB/IL2 Responders

From: Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

Stage Age Prior Systemic Therapy # Cycles Response
M1A (7/10) 59 None 4 PR
  78 None 2 SD
  83 None 2 MR
  64 ADI, BCT, αCTLA4, VAC 4 PR
  60 AIFN, BCT, TEM 4 PR
  45 ADI, IFN, VAC 4 PR
  75 AIFN, BCT 4 SD
M1B (1/8) 67 ADI 4 SD
M1C (14/42) 78 None 2 PR
  83 None 3 PR
  82 None 3 PR
  61 None 4 PR
  59 None 4 MR
  47 BCT, HDIL2, TKI258 3 PR
  62 αCTLA4 4 PR
  55 BCT, HDIL2, TKI258 4 MR
  70 ADI, BCT 2 MR
  30 BCT 4 MR
  30 BCT, HDIL2, αCTLA4, TKI258 2 MR
  45 BCT 4 MR
  61 BCT 3 MR
  58 ADI, VAC 4 MR
  1. Abbreviations: ADI adjuvant dacarbazine/low-dose IL-2; BCT biochemotherapy; αCTLA4 anti-cytotoxic T lymphocyte Antigen 4 antibody; VAC peptide vaccines; TEM temozolomide; IFN interferon; AIFN adjuvant interferon; HDIL2 high-dose IL-2; TKI258 tyrosine kinase inhibitor 258